公开(公告)号：US10590090B2

公开(公告)日：2020-03-17

申请号：US16228324

申请日：2018-12-20

申请人： Revolution Medicines, Inc.

发明人： Elena S. Koltun ,  Kevin Mellem ,  Adrian Gill ,  Gert Kiss ,  Christopher Semko ,  Naing Aay ,  Andreas Buckl ,  Ashutosh Jogalekar ,  Walter Won

IPC分类号： A61K31/497 ,  C07D241/20 ,  C07D403/12 ,  C07D403/04 ,  C07D241/18 ,  A61P35/02 ,  A61P35/04 ,  C07D401/04 ,  C07D477/26 ,  C07D487/04

摘要： The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.

公开(公告)号：US11673896B2

公开(公告)日：2023-06-13

申请号：US16518796

申请日：2019-07-22

申请人： Revolution Medicines, Inc.

发明人： Adrian Gill ,  Naing Aay ,  Kevin Mellem ,  Andreas Buckl ,  Elena S. Koltun ,  Christopher Semko ,  Gert Kiss

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D491/107

CPC分类号： C07D491/107 ,  C07D401/04 ,  C07D401/14

摘要： The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

公开(公告)号：US20230303591A1

公开(公告)日：2023-09-28

申请号：US17938890

申请日：2022-10-07

申请人： Revolution Medicines, Inc.

发明人： Andreas Buckl ,  G. Leslie Burnett ,  James Cregg ,  Anne V. Edwards ,  Adrian L. Gill ,  John E. Knox ,  Elena S. Koltun ,  Yang Liu ,  Christopher Semko

IPC分类号： C07D519/00 ,  A61P35/00

CPC分类号： C07D519/00 ,  A61P35/00 ,  C07B2200/05

摘要： The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

公开(公告)号：US11739093B2

公开(公告)日：2023-08-29

申请号：US16518798

申请日：2019-07-22

申请人： Revolution Medicines, Inc.

发明人： Brian R. Blank ,  Jennifer Pitzen ,  Gang Wang ,  Walter S. Won ,  Christos Tzitzilonis ,  Jie Jack Li ,  Elena S. Koltun ,  Naing Aay ,  Andreas Buckl ,  Kevin Mellem ,  Christopher Semko ,  Ash Jogalekar ,  Gert Kiss ,  Adrian Gill

IPC分类号： A61K31/4985 ,  C07D487/04 ,  C07D471/04 ,  C07D513/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D471/04 ,  C07D513/04 ,  C07D519/00

摘要： The present disclosure is directed to compounds of Formula IV:




as inhibitors of SHP2 and their use in the treatment of diseases associated with SHP2. Also disclosed are pharmaceutical compositions comprising the same.

公开(公告)号：US11661401B2

公开(公告)日：2023-05-30

申请号：US16905884

申请日：2020-06-18

申请人： Revolution Medicines, Inc.

发明人： Elena S. Koltun ,  Kevin Mellem ,  Adrian Gill ,  Gert Kiss ,  Christopher Semko ,  Naing Aay ,  Andreas Buckl ,  Ashutosh Jogalekar ,  Walter Won

IPC分类号： C07D401/04 ,  C07D241/20 ,  C07D403/12 ,  C07D403/04 ,  C07D241/18 ,  A61P35/02 ,  A61P35/04 ,  C07D477/26 ,  C07D487/04

CPC分类号： C07D241/20 ,  A61P35/02 ,  A61P35/04 ,  C07D241/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/12 ,  C07D477/26 ,  C07D487/04

摘要： The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.